{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:21:31Z","timestamp":1788337291354,"version":"build-2803163510"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Sugammadex, a modified \u03b3-cyclodextrin, rapidly and predictably reverses aminosteroid neuromuscular blockade by directly encapsulating rocuronium and vecuronium, thereby avoiding the cholinergic adverse effects associated with acetylcholinesterase inhibitors. Because both free sugammadex and the sugammadex\u2013rocuronium complex are eliminated predominantly through renal excretion, the use of sugammadex in patients with severe renal impairment remains a topic of debate. This review summarized current evidence on sugammadex by exploring its molecular mechanisms, pharmacokinetic and pharmacodynamic properties, clinical efficacy, and safety profile in patients with renal impairment. The literature indicates that severe renal impairment markedly prolongs the systemic retention of sugammadex and sugammadex\u2013rocuronium. However, this pharmacokinetic alteration does not compromise the rapid reversal of neuromuscular blockade or increase the risk of recurarization or major adverse events. High-flux hemodialysis increases the clearance of sugammadex\u2013rocuronium, but evidence supporting continuous renal replacement therapy and peritoneal dialysis remains limited. Overall, sugammadex may serve as an effective and generally well-tolerated reversal agent in carefully selected patients with severe renal impairment. Additional prospective studies are required to establish its long-term safety and guide clinical recommendations.<\/jats:p>","DOI":"10.3389\/fphar.2026.1932040","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:01:51Z","timestamp":1788336111000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical application of sugammadex in renal impairment: pharmacokinetics and pharmacodynamics"],"prefix":"10.3389","volume":"17","author":[{"given":"Hao-Wei","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Cathay General Hospital","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pao-Shan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Cathay General Hospital","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Jia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Cathay General Hospital","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Shung","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Cathay General Hospital","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1021\/jm011107f","article-title":"Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure\u2212activity relationships","volume":"45","author":"Adam","year":"2002","journal-title":"J. Med. Chem."},{"key":"B2","volume-title":"\u201cSugammadex.\u201d Nih.Gov","author":"Chandrasekhar","year":"2019"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1016\/j.jfma.2022.04.017","article-title":"Sugammadex reversal of muscle relaxant blockade provided less post-anesthesia care unit adverse effects than neostigmine\/glycopyrrolate","volume":"121","author":"Chang","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"key":"B4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.bja.2024.07.042","article-title":"Sugammadex hypersensitivity: a multicentre retrospective analysis of a large Australian cohort","volume":"134","author":"Crimmins","year":"2024","journal-title":"Br. J. Anaesth."},{"key":"B5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/MJT.0000000000000092","article-title":"Sugammadex: a scientific review including safety and efficacy, update on regulatory issues, and clinical use in Europe","volume":"22","author":"Jahr","year":"2015","journal-title":"Am. J. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/ALN.0b013e31818a3fee","article-title":"Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine","volume":"109","author":"Jones","year":"2008","journal-title":"Anesthesiology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.5414\/cp201976","article-title":"Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects","volume":"52","author":"Kam","year":"2014","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1213\/ane.0b013e3181ac53c3","article-title":"Sugammadex provides faster reversal of vecuroniuminduced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial","volume":"110","author":"Khuenl-Brady","year":"2010","journal-title":"Anesth. Analg."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3390\/medicina57111259","article-title":"Efficacy and safety of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in patients with end-stage renal disease: a systematic review and meta-analysis","volume":"57","author":"Kim","year":"2021","journal-title":"Med. Kaunas."},{"key":"B10","volume-title":"An Overview of Sugammadex. ATOTW 332 \u2013 an Overview of Sugammadex","author":"Mitchell","year":"2016"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.36303\/SAJAA.2020.26.6.S3.2555","article-title":"Sugammadex","volume":"26","author":"Mogane","year":"2020","journal-title":"South. Afr. J. Anaesth. Analg."},{"key":"B11","doi-asserted-by":"publisher","first-page":"302","DOI":"10.4103\/0259-1162.123211","article-title":"Sugammadex: a revolutionary drug in neuromuscular pharmacology","volume":"7","author":"Nag","year":"2013","journal-title":"Anesth. Essays Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3390\/jpm13091380","article-title":"Comparison between sugammadex and neostigmine after video-assisted thoracoscopic surgery\u2013thymectomy in patients with myasthenia gravis: a single-center retrospective exploratory analysis","volume":"13","author":"No","year":"2023","journal-title":"J. Personalized Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.17085\/apm.22259","article-title":"Sugammadex administration in patients with end-stage renal disease: a narrative review with recommendations","volume":"18","author":"Oh","year":"2023","journal-title":"Anesth. Pain Med. Seoul."},{"key":"B14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/bja\/aet586","article-title":"Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg-1 for reversal of deep neuromuscular blockade in patients with severe renal impairment","volume":"114","author":"Panhuizen","year":"2015","journal-title":"Br. J. Anaesth."},{"key":"B15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5114\/ait.2023.125337","article-title":"An appraisal of neostigmine versus sugammadex for neuromuscular blockade reversal in patients with a prior heart transplant","volume":"55","author":"Paredes","year":"2023","journal-title":"Anaesthesiol. Intensive Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/bja\/aep093","article-title":"Reversal of neuromuscular block","volume":"103","author":"Srivastava","year":"2009","journal-title":"Br. J. Anaesth."},{"key":"B17","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/bja\/aen216","article-title":"Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function","volume":"101","author":"Staals","year":"2008","journal-title":"Br. J. Anaesth."},{"key":"B18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/bja\/aep340","article-title":"Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study","volume":"104","author":"Staals","year":"2010","journal-title":"Br. J. Anaesth."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1046\/j.1523-1755.2003.00924.x","article-title":"Review on uremic toxins: classification, concentration, and interindividual variability","volume":"63","author":"Vanholder","year":"2003","journal-title":"Kidney Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/dddt.s2757","article-title":"Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent","volume":"2","author":"Welliver","year":"2008","journal-title":"Drug Des. Dev. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1932040\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:01:52Z","timestamp":1788336112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1932040\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":21,"alternative-id":["10.3389\/fphar.2026.1932040"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1932040","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"article-number":"1932040"}}